Venus' first manufacturing location commenced operation in 1991. This unit is for large volume parenterals with 7.5 million units per annum capacity. A proactive investment in world-class equipment and a strict adherence to best practices enable the unit to manufacture complex and intravenous products products in the Antibiotics, Total Parenteral Nutrition (TPN), Neuro and other super specialty therapeutic segments.
This five-acre unit represents a prudent balance between environment friendliness and globally-benchmarked manufacturing infrastructure.The unit manufactures high-end novel formulations across eight units dedicated to oncology liquid injections, oncology lyophilised, lyophilised injections, pre-filled syringes, cephalosporins, carbapenems, cardiology injections and liquid vials. The unit has an annual production capacity of 92.5 million.
Venus commenced its German operations in 2005 through Venus Pharma GmbH (wholly-owned subsidiary) to service the large European market. This unit is engaged in out-licensing CTDs, site variation projects, testing and batch release for Europe, warehousing and logistics support. Accredited with EU-GMP, this facility possesses world-class quality assurance, control laboratories and a warehousing capacity of 3,000 pallets under controlled temperature.
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to VRL India, its subsidiaries or affiliates. No use of any VRL India trademark, trade name, or trade dress in this site may be made without the prior written authorization of VRL India, except to identify the product or services of the company.